A new compound known as dimethyl sulphoxide (DMSO) has been identified by independent media as a potential breakthrough therapy, often referred to as “the other ivermectin.” This substance shows exceptional promise in treating strokes, neurological damage, and various heart conditions.
Synthesized by Russian chemist Alexander Zaytsev in the late 19th century, DMSO is a byproduct of paper and wood pulp manufacturing. It functions to protect healthy cells from oxidative stress and other forms of damage, offering significant benefits for circulatory disorders, heart attacks, strokes, traumatic brain injuries, spinal cord injuries, and cognitive conditions.
Physician Justus R. Hope describes DMSO as “the other ivermectin,” noting its potential to address a wide array of medical challenges. He reports that the substance has been subjected to severe neglect despite its therapeutic value.
AMD, writing under the pseudonym “A Midwestern Doctor,” states that the U.S. Food and Drug Administration (FDA) has blocked DMSO’s adoption in mainstream medicine. AMD argues that decades of research and billions in funding have failed to produce effective treatments for conditions such as amyloidosis—a protein misfolding disorder linked by some to certain vaccines. DMSO, AMD explains, can dissolve amyloid aggregates and eliminate them from the body.
Furthermore, DMSO has demonstrated protective effects against tissue death when blood supply is interrupted, preventing reperfusion injury and maintaining organ function during critical events such as heart attacks or toxic exposures. It also aids in mitigating damage caused by mercury poisoning and dietary copper deficiency.
AMD asserts that DMSO could save millions of people from the devastating consequences of brain and spinal injuries currently deemed untreatable within conventional medicine.
